A comprehensive and universal approach for embryo testing in patients with different genetic disorders

Shuo Zhang,Caixia Lei,Junping Wu,Min Xiao,Jing Zhou,Saijuan Zhu,Jing Fu,Daru Lu,Xiaoxi Sun,Congjian Xu
DOI: https://doi.org/10.1002/ctm2.490
IF: 8.554
2021-07-01
Clinical and Translational Medicine
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p><i>In vitro</i> fertilization (IVF) with preimplantation genetic testing (PGT) has markedly improved clinical pregnancy outcomes for carriers of gene mutations or chromosomal structural rearrangements by the selection of embryos free of disease-causing genes and chromosome abnormalities. However, for detecting whole or segmental chromosome aneuploidies, gene variants or balanced chromosome rearrangements in the same embryo require separate procedures, and none of the existing detection platforms is universal for all patients with different genetic disorders. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Here, we report a cost-effective, family-based haplotype phasing approach that can simultaneously evaluate multiple genetic variants, including monogenic disorders, aneuploidy, and balanced chromosome rearrangements in the same embryo with a single test. A total of 12 monogenic diseases carrier couples and either of them carried chromosomal rearrangements were enrolled simultaneously in this present study. Genome-wide genotyping was performed with single-nucleotide polymorphism (SNP)-array, and aneuploidies were analyzed through SNP allele frequency and Log R ratio. Parental haplotypes were phased by an available genotype from a close relative, and the embryonic genome-wide haplotypes were determined through family haplotype linkage analysis (FHLA). Disease-causing genes and chromosomal rearrangements were detected by haplotypes located within the 2 Mb region covering the targeted genes or breakpoint regions.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Twelve blastocysts were thawed, and then transferred into the uterus of female patients. Nine pregnancies had reached the second trimester and five healthy babies have been born. Fetus validation results, performed with the amniotic fluid or umbilical cord blood samples, were consistent with those at the blastocyst stage diagnosed by PGT.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>We demonstrate that SNP-based FHLA enables the accurate genetic detection of a wide spectrum of monogenic diseases and chromosome abnormalities in embryos, preventing the transfer of parental genetic abnormalities to the fetus. This method can be implemented as a universal platform for embryo testing in patients with different genetic disorders.</p></section>
oncology,medicine, research & experimental
What problem does this paper attempt to address?
### What problems does this paper attempt to solve? This paper aims to solve the problem of comprehensive and general genetic testing for patients with different genetic diseases before embryo implantation. Specifically, the researchers have developed a family - based haplotype - linkage analysis (FHLA) method based on single - nucleotide polymorphisms (SNP) to achieve simultaneous detection of monogenic diseases, chromosomal aneuploidy and balanced chromosomal rearrangements. This method can avoid the limitations of existing testing platforms, that is, they are unable to detect all these types of genetic abnormalities simultaneously and require different testing procedures to be carried out separately. #### Main problems: 1. **Simultaneous detection of multiple genetic abnormalities**: Existing testing platforms are usually only able to detect a specific type of genetic abnormality, such as monogenic diseases or chromosomal aneuploidy, and cannot evaluate multiple genetic variations in the same test. 2. **Generality and cost - effectiveness of testing**: Current methods are not only complex but also costly, and it is difficult to be widely applied in clinical practice. 3. **Avoiding the transmission of genetic abnormalities to the next generation**: Through accurate embryo testing, prevent embryos carrying pathogenic genes or chromosomal abnormalities from being transplanted, thereby avoiding the transmission of genetic diseases to the next generation. ### Research background and significance: - **Prevalence and impact of genetic diseases**: It is estimated that there are approximately 6,000 - 8,000 monogenic genetic diseases worldwide, and the number of affected people exceeds 200 million. Although the pathogenic genes of many rare diseases have been identified, only a very small number have treatment methods, so it is crucial to prevent the birth of pathogenic embryos. - **Impact of chromosomal rearrangements**: Chromosomal structural rearrangements (such as balanced translocations and inversions) can affect fertility, leading to miscarriage and congenital malformations. The incidence of such rearrangements is relatively high in couples with recurrent miscarriage. - **Limitations of existing technologies**: Although traditional pre - implantation genetic testing (PGT) techniques are effective, they have limitations in detecting multiple genetic abnormalities and require different testing procedures to be carried out separately, increasing complexity and cost. ### Solutions: - **SNP - based FHLA method**: Through SNP arrays and family - based haplotype - linkage analysis, monogenic diseases, chromosomal aneuploidy and balanced chromosomal rearrangements can be evaluated simultaneously in one test. This method not only improves the accuracy of detection but also reduces the cost, making it more suitable for a wide range of clinical applications. - **No need for an affected proband**: For monogenic diseases, this method does not require an affected family member (such as a proband), further simplifying the testing process. ### Conclusion: The research results show that the SNP - based FHLA method can accurately detect multiple genetic abnormalities in embryos, prevent embryos with genetic defects from being transplanted, and thus avoid the transmission of genetic diseases to the next generation. This method is cost - effective and highly general, and is expected to become a new platform widely used in pre - implantation genetic testing.